Skip to main content

Table 1 Demographic and clinical characteristics of the study population

From: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

   Study group Control group p-value
Subjects   155 161  
Age (years), mean (SD) 51.74 (12.05) 50.74 (13.12) 0.4801
Gender, n (%) Female 99 (63.9) 102 (63.4) 0.9239
Male 56 (36.1) 59 (36.6)
Ethnicity (%) Caucasian 145 (93.5) 147 (91.3) 0.6215
Latin American 7 (4.5) 10 (6.2)
Other 3 (2.0) 4 (2.5)
Time since diagnosis (months), mean (SD) 58.89 (93.29) 61.52 (95.80) 0.8050
Main diagnosis, n (%) Major depression 146 (94.2) 148 (91.9) 0.7035
Dysthymic disorder 5 (3.2) 8 (5.0)
Other non-specified depressive disorder 4 (2.6) 5 (3.1)
Clinical Global Impression-Severity (CGI-S) scale, clinician-rated, mean (SD) 4.50 (0.62) 4.40 (0.57) 0.1663
Hamilton Depression Rating Scale (HDRS-17), mean (SD) 19.47 (5.96) 19.01 (5.71) 0.4818
Patient Global Impression of Improvement scale (PGI-I), single-blinded inclusion criterion, n (%) No change 108 (69.7) 123 (76.4) 0.4026
A little worse 26 (16.8) 20 (12.4)
Much worse 16 (10.3) 16 (9.9)
Very much worse 5 (3.2) 2 (1.2)
Previous failed psychiatric medication trials, mean (SD)   2.55 (2.35) 2.57 (2.10) 0.9175